Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration.
Reactive oxygen species (ROS) are implicated in amphetamine-initiated neurodegeneration, but the mechanism is unclear. Here, we show that amphetamines are bioactivated by CNS prostaglandin H synthase (PHS) to free radical intermediates that cause ROS formation and neurodegenerative oxidative DNA damage. In vitro incubations of purified PHS-1 with 3,4-methylenedioxyamphetamine (MDA) and methamphetamine (METH) demonstrated PHS-catalyzed time- and concentration-dependent formation of an amphetamine carbon- and/or nitrogen-centered free radical intermediate, and stereoselective oxidative DNA damage, evidenced by 8-oxo-2'-deoxyguanosine (8-oxo-dG) formation. Similarly in vivo, MDA and METH caused dose- and time-dependent DNA oxidation in multiple brain regions, remarkably dependent on the regional PHS levels, including the striatum and substantia nigra, wherein neurodegeneration of dopaminergic nerve terminals was evidenced by decreased immunohistochemical staining of tyrosine hydroxylase. Motor impairment using the rotarod test was evident within 3 wk after the last drug dose, and persisted for at least 6 months. Pretreatment with the PHS inhibitor acetylsalicylic acid blocked MDA-initiated DNA oxidation and protected against functional motor impairment for at least 1.5 months after drug treatment. This is the first direct evidence for PHS-catalyzed bioactivation of amphetamines causing temporal and regional differences in CNS oxidative DNA damage directly related to structural and functional neurodegenerative consequences.
Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Winnie
W
Jeng
Annmarie
A
Ramkissoon
Toufan
T
Parman
Peter G
PG
Wells
D015104:3,4-Methylenedioxyamphetamine / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D018759:Adrenergic Uptake Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000662:Amphetamines / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001241:Aspirin; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D016861:Cyclooxygenase Inhibitors; D004247:DNA / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005609:Free Radicals / Q000378:metabolism*; D008694:Methamphetamine / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D015394:Molecular Structure; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010084:Oxidation-Reduction / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011597:Psychomotor Performance / Q000187:drug effects; D013569:Synapses / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*
D018759:Adrenergic Uptake Inhibitors; D000662:Amphetamines; D016861:Cyclooxygenase Inhibitors; D005609:Free Radicals; D008694:Methamphetamine; D015104:3,4-Methylenedioxyamphetamine; D004247:DNA; D011451:Prostaglandin-Endoperoxide Synthases; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D001241:Aspirin